A new report by the Gates Foundation has revealed that long-acting HIV prevention tools, such as lenacapavir, the twice-yearly HIV-prevention injection, offer some of the strongest opportunities to drive infections and deaths towards zero in high-burden countries.
The 2025 Goalkeepers Report, released on Thursday, highlights lenacapavir’s potential as a transformative HIV prevention option, particularly for women and adolescent girls who face barriers to using existing daily oral…
Read the full article here
